Substance abuse and addiction remain a serious problem across the United States, generating more than $700 billion a year in expenses related to health care, crime, work productivity and more, according to the National Institute on Drug Abuse (http://dtn.fm/pcN87). Abuse of tobacco, illicit drugs and alcohol remains high, along with the number of prescription drug users nationwide. Unfortunately, not all people suffering from a substance abuse problem get the treatment they need, or perhaps access to any kind of treatment at all, with potentially lethal consequences. GreeneStone Healthcare Corp. (OTCQB: GRST), a Canadian-founded provider of healthcare services, with a focus on addiction and mental health, is hoping to change this as it enters the U.S. market with a unique and tested approach to the substance abuse recovery process.

The company recently sold its Canadian addiction business and is planning to open a new treatment center in Florida after acquiring the real estate assets and business of Delray Beach-based Seastone addiction center. Known as a leading and first addiction treatment of the kind in Canada, GreeneStone has used modern philosophies and techniques to successfully treat hundreds of patients, and it has been planning to expand its operations to the U.S. as well. The first step is the Florida clinic, where the company hopes to use the skills acquired in Canada to revolutionize addiction treatment.

According to the Addiction Blog (http://dtn.fm/4irCC), Florida has a severe substance problem and one of the highest overdose mortality rates in the United States. With more than 300 illegal methamphetamine labs seized and almost 3,000 drug induced deaths per year, the need for comprehensive and effective substance abuse and addiction treatment is evident. In addition, Florida also prescribes up to 10 times more oxycodone pills than all the other states combined, which in turn causes a major increase in the number of addiction patients throughout the state.

GreeneStone’s unique approach to substance abuse recovery is based on the best practices and principles available and focuses on treating not only the addiction problem but also any co-occurring and underlying disorders that enabled the addiction behavior in the first place. GreeneStone applies unique assessment tools to evaluate the extent and nature of the brain disorders in its clients so that it may effectively tailor the treatment plan. With a non-judgmental, client-centered approach that respects the need for privacy, independence and autonomy and embraces diversity, GreeneStone is developing personalized, holistic treatments for its patients, based on their individual beliefs and situation.

Additionally, all treatments are results oriented and based on the idea of inclusion – meaning that each client benefits from core team support consisting of friends or family. Counseling and education are also provided to family members and friends who are part of patients’ support teams, with the goal of helping them get a better understanding of what their loved ones are going through, what addiction entails and how they can help during and after the recovery process.

For more information, visit the company’s website at www.GreeneStone.net

Drug development. Medical marijuana. Female diagnostics and treatments. These high-growth industries and sectors are the focal points of Easton Pharmaceuticals, Inc.’s (OTC: EAPH) operations. A diversified and specialty company based in Canada, Easton’s operation spans multiple pharmaceutical sectors and other emergent industries, including the medical marijuana market.

In its day-to-day operations, the company balances three mission goals:

1. It develops and acquires drugs, diagnostics and treatment products that build shareholder value.
2. It delivers safe, effective and proven products that improve the health and well-being of men and women across global jurisdictions.
3. It builds and capitalizes on fast-growing and promising industries and sectors defined by products like medical marijuana, vaporizers, e-liquids and other items.

Within the pharmaceutical sector, Easton designs, develops and markets a variety of topical drugs and therapeutic health care products. It formerly developed and owned a wound-healing drug approved the U.S. Food and Drug Administration. Presently, however, its portfolio includes products in various stages of development and approval, from topically-delivered drugs that treat cancer to therapeutic products that treat varied conditions. For one, Easton is the midst of developing XILIVE, an early stage cancer drug. For another, it is growing its product portfolio, which currently includes: Kenestrin Gel used for arthritic pain and pain in the back, elbows, knees, shoulders and wrist; Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Viorra, a hormone-free, non-toxic, and topical gel that improves a woman’s sexual functioning; and a female sexual arousal disorder drug.

Another key product in Easton’s portfolio is AL-Sense (AmnioSense), an amniotic fluid diagnostic leak test. Through a strategic partnership, Easton and another company, BMV Medica SA de C.V., own the exclusive distribution rights for AL-Sense (AmnioSense) in Mexico and Latin America. AL-Sense (AmnioSense) is a patented women’s diagnostic product that has been approved in Europe and is already being sold in the United Kingdom. With the birth rate in Latin America estimated at three times that of North America and most of Europe, it opens up a vast market for the Easton / BMV partnership, one with a population greater than 200 million people. The higher birthrate in the region and other factors also portend a faster rate of sale for pharmaceutical and diagnostic products, approximately five times the rate of North American and European sales.

For more information, visit www.EastonPharmaceuticalsInc.com

National Waste Management Holdings (OTC: NWMH) is turning trash into treasure in its run-up to becoming a leading waste management company in the United States. Specializing in a multitude of solid waste management services, the company recognizes the promise in this highly-regulated industry and is pursuing a growth strategy that merges supplementary acquisitions with organic initiatives.

Over 20 years ago, National Waste established a presence in Hernando, Florida – the base of its operations – before extending its reach to the state of New York. Fast forward to today, and the company is focused on hastening its growth and leveraging the resources at its disposal, including:

• The backing of its tested leadership team;
• Industry trends, including national recycling mandates;
• Prospective increases in residential construction and infrastructure spending; and
• Strategic company acquisitions.

Operationally, National Waste specializes in services surrounding the removal and hauling off of debris, garbage and waste. The company offers construction and demolition landfill services; commercial and residential dumpster services and roll-off boxes for construction and clean-up projects. It also provides trash collection services and a full service transfer station, as well as wood grinding, demolition, mulch and gravel services for industrial and residential markets.

These days, National Waste continues to press forward with an aggressive business model that calls for one acquisition per quarter by seeking out acquisitive opportunities in Upstate New York and Florida. To name a few, the company acquired both Sivart Services, a roll-off and compactor company in Worchester, NY, and Northeast Data Destruction and Recycling in 2016. More recently, in February 2017, National Waste targeted and closed on another acquisition in the area. This time, it acquired Burts Refuse, a waste disposal and recycling business in West Davenport, NY.

National Waste’s recent acquisitions add to its existing operations while making way for future growth. These deals expand its territory for commercial and residential garbage collection in Upstate New York, increase its roll-off customer base and business relationships and strengthen its equipment line with additional trucks, equipment and containers. They also create overhead cost savings for the company and introduce new income streams to its books.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

Chinese consumers are spending more, and that harbors good fortune for Moxian, Inc. (NASDAQ: MOXC) as it continues to roll out its comprehensive online-to-offline (O2O) commercial platform. Consumption in China as a percentage of GDP is rising, and retail sales went up by about 10 percent in 2016. There’s no doubt that consumption is driving commerce and that the Moxian platform that links brick-and-mortar establishments to the cloud is at the hub of online and offline commercial activity.

Reuters (http://nnw.fm/Yf4xs) recently reported on data released by China’s statistics bureau that showed consumption accounted for about three-quarters of China’s economic growth in the first half of 2016. In the past, a lot of China’s GDP growth has come from capital investment and exports, and consumption since the Great Recession has been around 36 percent of GDP. The 2016 reported figure would indicate that the Chinese economy is on its way to becoming consumer driven, much as Western economies are. Consumption contributes to more than half of GDP in most developed economies. In the U.S., it accounts for about two-thirds of economic activity.

Other data shows that, indeed, the normally thrifty Chinese are loosening their purse strings. While the Chinese economy is expected to grow by 6.7 percent in 2016, according to the International Monetary Fund (IMF) (http://nnw.fm/l1NyB), China Daily (http://nnw.fm/k7IH1) reported that retail sales in China rose by 9.6 percent in 2016. Retail is growing 40 percent faster than the economy.

Moxian is set to capitalize on these changing dynamics. It is planning a renewed marketing push of its Moxian+ platform this month. The company now has operations in two major Chinese cities, Shenzhen and Beijing, and plans to expand into two more, Shanghai and Guangzhou, with a sales force of around 100 by the end of 2017. The sales effort will be directed to both increasing the number of merchants using the free version of the platform and converting ‘free’ users to Moxian’s added subscription services. The free version of Moxian’s platform is already in use by more than 30,000 businesses and 300,000 consumers, mostly in Shenzhen.

Shenzhen is one of China’s top five cities, according to China Highlights (http://nnw.fm/K60Nq), with a population of around 10 million. The city has the distinction of being home to China’s first Special Economic Zone (SEZ), created in 1980, and the level of financial and investment activity has merited the establishment of its own Shenzhen Stock Exchange (SZSE), now the world’s eighth largest, listing companies with a total capitalization of around $2.3 trillion.

Beijing, of course, is the capital of the People’s Republic of China, with a population of about 19 million and an economy estimated (http://nnw.fm/eT87j) at around $360 billion in 2016. Guangzhou is also a major Chinese city. It has a population of about 11 million and is noted for the large number of foreigners living there. Biggest and brightest of all, however, is Shanghai, with its population of some 24 million. China Highlights ranks it as the number one city, boasting that it is ‘the undisputed largest and wealthiest city in China’.

Based in Shenzhen, China, Moxian has developed a technology platform, Moxian+, which provides small- and medium-sized enterprises (SMEs) with technology tools to manage and conduct business through mobile, online, and social media channels. Moxian+ is targeted at SMEs with traditional, offline, or “brick and mortar” businesses, providing them with a full suite of O2O commerce services. With a footprint in China’s top cities, the company looks set to do some business.

For more information, visit www.Moxian.com

Vertex Energy, Inc. (NASDAQ: VTNR), an environmental services company that focuses on aggregating, processing, and recycling industrial waste systems and off-specification commercial chemical products, is taking strides toward conserving the environmental and energy resources of the United States by operating in three key divisions: Black Oil, Refining & Marketing, and Recovery.

The Black Oil Division collects, aggregates, processes, and then sells used motor oil (UMO) and finished products, while the Refining & Marketing Division aggregates and manages the refining of off-specification petroleum and chemical products. Lastly, the Recovery Division provides hydrocarbon stream recovery and management solutions, industrial dismantling and demolition, and decommissioning services.

Vertex Energy also uses a variety of refining technologies. These include base oil, VGO, and TCEP, with refineries located in Columbus, Ohio; Marrero, Louisiana; and four other terminals. These aggregate UMO collected from across eight to 10 major metropolitan areas.

The company is made up of third-party aggregation systems with approximately 50 collectors, 43 trucks operating as collectors, a nationwide processing capacity of over 115 million gallons, and in-depth market knowledge that enables its sales model to foster strong, localized relationships. VTNR now has 2 terminals for aggregation in Houston and Mobile, and it has developed and patented a unique UMO processing technology.

Although Vertex Energy still has a presence across the country, taking on 23 percent of total UMO refining capacity in North America, it now operates in strategic regional hubs, allowing it to optimize its transportation costs. The company has two refining facilities in Texas, two in Louisiana, and one in Ohio. All of these have a diversification of product mix, with one in Baytown strategically located to capitalize on the export market created by Gulf refiners, and one which is capable of low-capex conversion, allowing it to produce base oil.

Most recently, Vertex announced its fourth quarter and end-of-year financial results for 2016. For the three months ended December 31, 2016, the company reported revenues of over $31 million, a growth of nearly 50 percent compared to the same period of 2015. VTNR’s gross profits came in at over $5 million, more than 1,000 percent higher than the previous year, with a gross profit margin of 17 percent. Additionally, the company’s SG&A expenses decreased more than 30 percent compared to the same period of the previous year, and per-barrel margin improved more than 1,000 percent.

Overall, Vertex reported revenues of more than $98 million, with profits exceeding last year’s figure by over $5 million, and a gross profit margin 10 percent higher than in 2015. During 2016, the company reduced debts and stabilized itself. VTNR expects increased volume in 2017.

Recently, analysts have shown significant interest in Vertex Energy, with the majority of these offering the company a ‘Buy’ or ‘Strong Buy’ recommendation on the stock. Rives Journal states that some analysts project the stock to reach $2.13 in the near future (http://dtn.fm/0NnCI). Zacks Investment Research upgraded Vertex from a ‘Hold’ rating to a ‘Buy’ rating with a price objective of $1.50 per share, all according to Daily Quint (http://dtn.fm/zGd6B).

Institutional investors raised their positions in the company, giving them ownership of 21.51 percent of Vertex’s stock. On March 1, 2017, Vertex Energy traded up over 4 percent, reaching $1.41. As it stands today, the company has a market cap of just over $39 million.

For more information, visit www.VertexEnergy.com

According to a new market report published by Credence Research (http://dtn.fm/FV2Gi) entitled ‘Head Mounted Display (HMD) (Defense, Consumer, Industrial, Healthcare, Public Safety, and Other Verticals) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast 2015 – 2022’, the head mounted display market is expected to expand at a compound annual growth rate of just below 50% between 2015 and 2022.

The report explains that this significant growth has been largely attributed to the declining prices of microdisplays, coupled with the high demand for lightweight wearable computing devices. Because of this decline in prices, manufacturers are now able to penetrate into the consumer market, offering more affordable products.

eMagin Corp. (NYSE MKT: EMAN), a company dedicated to developing and delivering head-worn systems for law enforcement, military, entertainment, and medical applications, among others, is set to capitalize on this growing industry thanks to its ability to develop and deliver high-quality, high-resolution, cutting-edge displays to its customers.

Earlier this week, the company was a big mover, with a rise in shares of more than 9% on March 7, 2017. According to the Nasdaq website (http://dtn.fm/YhZ6q), “The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.10 to $2.30 in the past one-month time frame.” The company’s stock price escalated, climbing to $2.45 per share in Friday morning trading.

On March 8, the Daily Quint reported that Bessemer Group, Inc. had acquired over 76,000 new shares of eMagin stock worth approximately $164,000 (http://dtn.fm/9QusN). Not only this, Fiscal Standard (http://dtn.fm/l8xRG) reported that H. C. Wainright and Craig Hallum began coverage on the company, with both issuing it a ‘Buy’ rating. Craig Hallum gave eMagin a target share price of $6.

eMagin is the first and leading manufacturer of active matrix OLED-on-silicon microdisplays. In addition to the company’s focus on the security, defense, medical, and industrial markets, eMagin has now entered into the consumer market with its Z800 3DVisor, which was described as the “the best 3D goggles we’ve ever tested” by Maximum PC (http://dtn.fm/zyV67).

For more information, visit www.eMagin.com

Singlepoint, Inc. (OTC: SING), a publicly traded holding company based in Arizona, has been highlighted as one to look out for in the cannabis space, according to InsiderFinancial.com (http://dtn.fm/3zGnN). The company, through its SingleSeed subsidiary, provides business services to cannabis businesses, including marketing, point of sale and more.

Because of the company’s nature, and its ability to fill a very challenging gap in the marijuana industry, Singlepoint is on a climb as the industry continues to flourish in the United States. This has been reflected in its stock price, which at the time of InsiderFinancial’s coverage had shown a 560% appreciation in approximately 12 weeks.

In addition to its substantial stock rise, earlier this year Singlepoint announced that it has raised more than $600,000, and it is looking to secure up to $1 million. Singlepoint has also made reference to its strategic acquisition activities.

During an interview with Donald Baillargeon from Money TV (http://dtn.fm/e27Za), CEO Greg Lambrecht explained that the companies Singlepoint is looking to acquire are those that are part of the cannabis industry, but that do not in any way touch the plant itself. This acquisition strategy allows Singlepoint to continue expanding without getting into trouble with any state or federal laws.

According to InsiderFinancial, the acquisition announcement relates to a company called Convectium, which has invented a mechanism that fills over 100 oil cartridges in just 30 seconds. Because of the high demand for this type of infrastructural technology, Singlepoint is expected to close this acquisition in the very near future.

According to Lambrecht and InsiderFinancial, Singlepoint’s key goals are to close its acquisition of Convectium, look for more acquisitions to close in the future, and continue to raise money for the company. With a market cap that has grown from just $5 million to over $40 million, and a significant amount of attention from new investors and other third parties, analysts believe that Singlepoint will continue to show signs of growth for the foreseeable future.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

At the recently held Conference on Retroviruses and Opportunistic Infections at the Washington State Convention Center in Seattle, details of clinical trial results presented by CytoDyn Inc. (OTCQB: CYDY) for its monoclonal antibody, PRO 140, were well received. The UK-based charity, NAM Aidsmap, known for its pioneering work in providing information on HIV/AIDS therapies, hailed the poster presentations on monoclonal antibodies such as PRO 140, noting the promise they hold as long-acting therapies for HIV/AIDS patients with limited treatment options due to drug resistance (http://nnw.fm/dFPp2). PRO 140’s efficacy has already offered hope to a number of HIV positive patients in a series of clinical trials. On behalf of CytoDyn, Dr. Kush Dhody of Amarex Clinical Research presented, in a well-attended special themed discussion, the latest results from the extension study of a Phase IIb trial of PRO 140 as a single agent maintenance therapy for people who had achieved viral suppression on standard combination antiretroviral therapy (ART) and wanted to switch to a treatment with fewer side effects to improve their quality of life and provide simpler compliance.

Antibodies are produced by the body as a first line of defense against pathogens such as viruses and bacteria. Each antibody is uniquely developed to combat a particular antigen, which it then counters by flagging the intruder as such, to be destroyed by microphages, or by neutralizing it. Monoclonal antibodies are artificially produced antibodies that have been cloned from one cell, hence the term “monoclonal”. Being clones, antibodies produced from one cell are identical, and this means that large numbers of a specific antibody can be produced to fight the unique antigens associated with a pathogen.

This characteristic of selectively targeting a pathogen has given antibodies the moniker ‘magic bullets’, since they attack the disease-carrying cells without harming the host. The term was first proposed by German physician Paul Ehrlich, whose insights into the operation of these immunological mechanisms earned him the Nobel Prize in 1908.

PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment and has been used in more than 140 HIV positive patients in placebo controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and has been designated a “fast track” product candidate by the FDA.

If approved for commercialization, PRO 140 could face a $20 billion U.S. HIV therapeutics market that is plagued with a number of ills, including difficult dosing schedules, resistance to currently used drugs, and, worst of all, the debilitating toxicity of standard highly active antiretroviral therapy (HAART). PRO 140 has been shown to address the weaknesses of HAART with no serious side effects, hardly any toxicity and no drug resistance when self-administered as a dose-a-week subcutaneous injection. Despite advances in the prevention and treatment of HIV/AIDS, the scourge still afflicts ‘more than 1.2 million people in the U.S.’, according to the Centers for Disease Control and Prevention (http://nnw.fm/b5LWn). With PRO 140, CytoDyn is offering the hope of a longer and richer lifespan to many of those.

CytoDyn is a biotechnology company focused on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.

For more information, visit www.CytoDyn.com

SolarWindow Technologies, Inc. (OTCQB: WNDW), on February 7, 2017, was named as a winner in the 2017 BIG Innovations Awards presented by the Business Intelligence Group (http://dtn.fm/Nb3Yd), an organization of business executives who utilize a proprietary formula to recognize superior performance. The company is a technology firm that develops transparent, electricity-generating coatings for windows on tall towers. Its product was one of only four named a ‘shining star’ of innovation and a Chairman’s Choice winner.

The coatings supplied by SolarWindow Technologies, Inc. have the potential to turn a skyscraper into a ‘clean power generator’, the company announced. Its veneers can generate electricity using either natural or artificial light, in shaded areas, and even reflected and diffused light. They can be applied to all sides of a tall building, and they’re capable of realizing electricity savings of up to 50% annually, the company said, noting that it could return a one-year financial payback. This potential return was validated by independent engineering studies, according to SolarWindow.

The coatings are designed to produce electricity through transparent and organic photovoltaic (PV) coatings applied to the glass and flexible plastic for applications to tall buildings. As a result, normally passive windows are transformed into electricity producers. The potential one-year payback has been seen on a 50-story building. The company’s technology can also provide more than 15 times the environmental benefits of a conventional solar rooftop PV system.

In a news release, Maria Jimenez, chief operating officer of the Business Intelligence Group, said, “We are thrilled to be honoring SolarWindow as they are leading by example and making real progress on improving the daily lives of so many.”

John A. Conklin, president and CEO of SolarWindow, added, “We are honored to be recognized by this distinguished panel of business leaders for our work in developing possibly the biggest single breakthrough in clean energy — converting the solar rays of the sun into electricity on skyscrapers the world over.”

For more information, visit www.SolarWindow.com

Advanced Medical Isotope Corporation (OTC: ADMD), a late-stage radiation oncology-focused medical device company, has developed a real power play portfolio in the radiotherapy segment of the cancer treatment market, a niche set to hit $11.3 billion on its own by 2025 globally, growing at an estimated 6.7 percent CAGR. Brachytherapy, or placing radioactive implants directly on or into cancerous tissue, is a component of this sector; however, brachytherapy hasn’t seen the kind of traction historically that an innovator like ADMD stands poised to wrest out of it. The brachytherapy market ran about $705 million in 2015 and consisted of a 60/40 mix between HDR/LDR (high- and low-dose radiation) or pulsed therapies on the one hand, and microsphere brachytherapy on the other.

A Market Ripe for Disruption

Even with somewhat innovative developments like microspheres helping to drive growth estimates of some eight percent CAGR for the overall brachytherapy space, and projections of $2 billion by 2030, only ten or so companies currently dominate this heavily consolidated space. Most microsphere solutions pose migration risk, require pretreatment of the patient (which only somewhat mitigates the migration problem), and carry similar risks to other radiotherapies when it comes to the overall impact to surrounding healthy tissues. Microspheres are also typically quite limited in terms of what types of cancers/tissue systems they can effectively address, with liver cancer treatments like Australian company Sirtex’s (OTC: SXMDF) SIR-Spheres® being the obvious analogy.

This is where a company like ADMD really stands out from the competition with its Yttrium-90 (Y-90) based radiotherapy solutions, such as the Y-90 RadioGel™ device (ruled a medical device by the FDA in 2013) which is a highly localized direct delivery technology that is injected into the tumor. Y-90 RadioGel delivers an exceptional therapeutic ratio (high degree of dose delivered to cancer tissues, relative to impact on normal tissues) thanks to Y-90’s short-range, which effectively delimits radiation impact to surrounding tissues. RadioGel promises to offer a superior therapeutic profile compared to existing solutions in the brachytherapy segment, even innovations such as Y-90 microspheres that pose significant migration risks, and thus still carry the standard risk to normal surrounding tissues.

Unlike more expensive brachytherapy industry standard isotopes such as Cesium-131, Iodine-125, or Palladium-103 (which primarily emit auger x-rays of an infinite path length, use complex/costly delivery systems, and have a half-life ranging from 9.7 to 60 days), Yttrium-90 has a very short path length of only 4mm, a half-life of just 2.7 days, and is considerably less expensive/more accessible. This means Y-90 solutions are much safer to handle for healthcare professionals, treatment times are sizably reduced, and huge cost savings can find their way to the consumer. Perhaps most importantly though, is the earlier point about how Y-90 RadioGel is not limited to a handful of tumor/cancer types, as is the case with most microsphere or seed-based brachytherapy products.

Tech Portfolio Coverage Hints at Upper Limit Potential

Not content to rest on the laurels of a brachytherapy device like RadioGel, which obliterates the migration problem and has shown in studies that greater than 99 percent of the radiation stays in the tumor, the company has also developed a new approach to so-called permanent seed brachytherapy as well. ADMD’s Y-90 Fast-Resorbable Polymer Seeds (which contain RadioGel), unlike the industry standard glass or titanium seeds (which are packed with radioactive material and then injected to the tumor site), are fully resorbable/biodegradable and leave no casing behind.

The contrast couldn’t be more apparent between these proprietary polymer seeds containing RadioGel, and standard permanent seed therapy in the typical use scenario of prostate cancer. The RadioGel-containing polymer seeds are administered via a minimally invasive procedure that only requires small-gauge needles, whereas the standard permanent seed therapy uses up to 30 large needles, which inject seeds whose casings are left behind. Put yourself in the shoes of a patient for even five seconds and the contrast becomes glaringly obvious.

ADMD has even developed a Y-90 Polymer Topical Paste product engineered for direct application to tissues after a tumor resection, where it works hard to kill off any residual tumor cells that got missed during the surgery. This is an important product due to the constant fear of cancer recurrence, which has been a PR black-eye for the oncology community, and is indeed quite devastating to brave cancer survivors. Going through all the cost, suffering, and difficulties of cancer treatment, only to have the cancer come back, is a living nightmare that is all too common among cancer patients.

The short-range beta radiation emitted by Y-90 particles offers such high therapeutic index possibilities that the products ADMD has developed could even help to gradually reshape the standards of care within the broader cancer treatment market. And brachytherapy, one of the oldest known approaches to radiotherapy, could see a big, big resurgence. The company has exclusively licensed the Y-90 polymer composite tech (which was developed at Pacific Northwest National Laboratory) from the legendary Battelle Memorial Institute, one of the top government/commercial research institutes in the world.

ADMD is On the March, Pet Oncology is the Spear Tip

The company achieved an important milestone in late February 2017 with its fourth letter in a series of communications with the FDA, wherein the company identifies skin cancer (basal cell and squamous) as the primary indication via which RadioGel will be pushed towards FDA submittal and commercialization. An excellent choice given the laborious complexities of skin cancer surgeries and their post-op complications. These issues are particularly vexing for elderly patients, who have skin that is usually significantly thinner and much less robust.

With some 3.3 million or more skin cancer patients in the U.S. alone, many of whom have more than one tumor, it is reasonable to assert that the superior therapeutic profile of ADMD’s RadioGel could see the product rapidly become the indication of choice preferred by both patients and healthcare professionals alike. Looking at the technology portfolio here and the broad range of cancer types that can be treated using ADMD’s products, it should be tantalizing to investors just how much of the roughly $113 billion global cancer therapy market the company could eventually gobble up. Particularly when one considers the 7.4 percent CAGR projections for the industry as a whole through 2021. Post-commercialization, once the word about this technology really starts getting out to consumers, ADMD could be sitting on a gold mine.

The company also released a key letter to shareholders in February, mapping the new and streamlined path forward to FDA submission, which also contained a more formal introduction of new management appointed at the end of 2016. It included the appointment of a new CEO by the Board of Directors, Dr. Michael Korenko, and the appointment of Dr. Carlton Cadwell as Chairman. It’s a serious move by ADMD to show the FDA that they are not only listening, but taking guidance as gospel.

As a prominent indicator of just how aggressive the company really is about commercialization, one need only look at its emphasis on the veterinary oncology market. This is something of an open trade secret these days in biopharma: if you want to rapid-prototype your way into human use as a novel medical device developer, on-ramp via the pet market (if you are lucky enough to be able to).

Advanced Medical Isotope Corporation’s wholly-owned IsoPet Solutions subsidiary just announced late last year in October that the first animal, a cat, had received initial treatment with the pet version of the Y-90 RadioGel. This study will generate important data and help to advance the product towards commercialization in the veterinary market, paving the way for longer-term human use approval by the FDA. This is an exciting forward vector for the company, given the Trump administration’s vow in February to massively overhaul the FDA, with an emphasis on speeding up the pace at which new drugs come to market.

Looking at just the veterinary oncology market we have a winning proposition with ADMD’s Y-90 tech portfolio, given that roughly half of all dogs and around one third of all cats will be diagnosed with cancer in their lifetime. There are around 85.8 million cats and 77.8 million dogs in the country and we now live in an age where pets are essentially bonafide members of the family. The preceding statistic should color the likely much broader incident rate of undiagnosed cancers in cats and dogs, and throw light on the comparatively much cheaper/effective radiotherapy solutions ADMD is developing. Cancer is the leading cause of mortality in cats and dogs alike, with the average radiation treatment for dogs currently costing from around $5,000 to $7,000.

People love their pets but that is a hefty price tag for the average consumer. IsoPet Solutions could place effective pet cancer treatment for a broad range of caner types well within comfortable striking distance for millions of average consumer households. Ask around, comprehensive cancer treatment for pets is simply not doable for most people today, as the average pet owner simply cannot afford to shell out that kind of capital, even for a cherished pet whom they consider a genuine member of the family. The PR upside for ADMD on this subject alone basically writes itself. As an investor, one can just imagine the publicity boon from being able to make such a boast to pet owners, as having an effective/affordable cancer treatment to save the lives of their cats and dogs.

The proven efficacy of radioisotopes for melting cancer in a localized fashion, further hyper-localized and made safer by the company in terms of impact to surrounding tissues, is an easy sell. ADMD is a very interesting play in the oncology space with some serious potential due to broad spectrum applicability of the tech, and is currently trading near the bottom of the 52-week range ($0.07 to $1.00) at approximately $0.15/share.

To take a closer look, visit https://www.isotopeworld.com and http://www.isopetsolutions.com